Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jae-Cheol Lee

Showing results (161-170 of 226) with videos related to

Pageof 23
Sort By:
Oncoimmunology|September 14, 2020
Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitorsSang Eun Won, Hyo Jung Park, Sangil Byun, et al.
Journal of Clinical Medicine|January 21, 2022
CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung CancerYunha Nam, Chang-Min Choi, Young Soo Park, et al.
Cancer|November 12, 2009
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancerDae Ho Lee, Sang-We Kim, Cheolwon Suh, et al.
Biochemical and Biophysical Research Communications|March 7, 2006
Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sitesSoyoung Kim, Jae Ku Kang, Yong Kee Kim, et al.
Cancer Research and Treatment|January 16, 2024
Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World DataJeong Yun Jang, Si Yeol Song, Young Seob Shin, et al.
Cancer Research|October 30, 2013
MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activationJin Kyung Rho, Yun Jung Choi, Seon Ye Kim, et al.
BMC Cancer|December 28, 2013
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancerWonjun Ji, Chang-Min Choi, Jin Kyung Rho, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2007
Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective studyIm Il Na, Gi Jeong Cheon, Du Hwan Choe, et al.
Tuberculosis and Respiratory Diseases|January 16, 2013
Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE)Kwan-Ho Lee, Kye-Young Lee, Young-June Jeon, et al.
Translational Lung Cancer Research|August 13, 2025
Efficacy and safety of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in retreatment of patients without T790MJuwhan Choi, Jae Cheol Lee, In Ae Kim, et al.
Pageof 23

Showing results (161-170 of 226) with videos related to

Sort By:
Pageof 23
Oncoimmunology|September 14, 2020
Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitorsSang Eun Won, Hyo Jung Park, Sangil Byun, et al.
Journal of Clinical Medicine|January 21, 2022
CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung CancerYunha Nam, Chang-Min Choi, Young Soo Park, et al.
Cancer|November 12, 2009
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancerDae Ho Lee, Sang-We Kim, Cheolwon Suh, et al.
Biochemical and Biophysical Research Communications|March 7, 2006
Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sitesSoyoung Kim, Jae Ku Kang, Yong Kee Kim, et al.
Cancer Research and Treatment|January 16, 2024
Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World DataJeong Yun Jang, Si Yeol Song, Young Seob Shin, et al.
Cancer Research|October 30, 2013
MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activationJin Kyung Rho, Yun Jung Choi, Seon Ye Kim, et al.
BMC Cancer|December 28, 2013
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancerWonjun Ji, Chang-Min Choi, Jin Kyung Rho, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2007
Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective studyIm Il Na, Gi Jeong Cheon, Du Hwan Choe, et al.
Tuberculosis and Respiratory Diseases|January 16, 2013
Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE)Kwan-Ho Lee, Kye-Young Lee, Young-June Jeon, et al.
Translational Lung Cancer Research|August 13, 2025
Efficacy and safety of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in retreatment of patients without T790MJuwhan Choi, Jae Cheol Lee, In Ae Kim, et al.
Pageof 23